Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities

M. Navrátil, J. Tykvart, J. Schimer, P. Pachl, V. Navrátil, TA. Rokob, K. Hlouchová, L. Rulíšek, J. Konvalinka,

. 2016 ; 283 (13) : 2528-45. [pub] 20160606

Language English Country England, Great Britain

Document type Comparative Study, Journal Article

E-resources Online Full text

NLK Free Medical Journals from 2005 to 1 year ago
Medline Complete (EBSCOhost) from 2005-01-01 to 1 year ago
Wiley Free Content from 2005 to 1 year ago

UNLABELLED: Glutamate carboxypeptidase III (GCPIII) is best known as a homologue of glutamate carboxypeptidase II [GCPII; also known as prostate-specific membrane antigen (PSMA)], a protease involved in neurological disorders and overexpressed in a number of solid cancers. However, mouse GCPIII was recently shown to cleave β-citrylglutamate (BCG), suggesting that these two closely related enzymes have distinct functions. To develop a tool to dissect, evaluate and quantify the activities of human GCPII and GCPIII, we analysed the catalytic efficiencies of these enzymes towards three physiological substrates. We observed a high efficiency of BCG cleavage by GCPIII but not GCPII. We also identified a strong modulation of GCPIII enzymatic activity by divalent cations, while we did not observe this effect for GCPII. Additionally, we used X-ray crystallography and computational modelling (quantum and molecular mechanical calculations) to describe the mechanism of BCG binding to the active sites of GCPII and GCPIII, respectively. Finally, we took advantage of the substantial differences in the enzymatic efficiencies of GCPII and GCPIII towards their substrates, using enzymatic assays for specific detection of these proteins in human tissues. Our findings suggest that GCPIII may not act merely as a complementary enzyme to GCPII, and it more likely possesses a specific physiological function related to BCG metabolism in the human body. DATABASE: The X-ray structure of GCPII Glu424Ala in complex with BCG has been deposited in the RCSB Protein Data Bank under accession code 5F09.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023966
003      
CZ-PrNML
005      
20170720123614.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/febs.13761 $2 doi
035    __
$a (PubMed)27208881
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Navrátil, Michal $u Institute of Organic Chemistry and Biochemistry, Gilead Sciences and IOCB Research Centre, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Faculty of Natural Sciences, Charles University in Prague, Czech Republic.
245    10
$a Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities / $c M. Navrátil, J. Tykvart, J. Schimer, P. Pachl, V. Navrátil, TA. Rokob, K. Hlouchová, L. Rulíšek, J. Konvalinka,
520    9_
$a UNLABELLED: Glutamate carboxypeptidase III (GCPIII) is best known as a homologue of glutamate carboxypeptidase II [GCPII; also known as prostate-specific membrane antigen (PSMA)], a protease involved in neurological disorders and overexpressed in a number of solid cancers. However, mouse GCPIII was recently shown to cleave β-citrylglutamate (BCG), suggesting that these two closely related enzymes have distinct functions. To develop a tool to dissect, evaluate and quantify the activities of human GCPII and GCPIII, we analysed the catalytic efficiencies of these enzymes towards three physiological substrates. We observed a high efficiency of BCG cleavage by GCPIII but not GCPII. We also identified a strong modulation of GCPIII enzymatic activity by divalent cations, while we did not observe this effect for GCPII. Additionally, we used X-ray crystallography and computational modelling (quantum and molecular mechanical calculations) to describe the mechanism of BCG binding to the active sites of GCPII and GCPIII, respectively. Finally, we took advantage of the substantial differences in the enzymatic efficiencies of GCPII and GCPIII towards their substrates, using enzymatic assays for specific detection of these proteins in human tissues. Our findings suggest that GCPIII may not act merely as a complementary enzyme to GCPII, and it more likely possesses a specific physiological function related to BCG metabolism in the human body. DATABASE: The X-ray structure of GCPII Glu424Ala in complex with BCG has been deposited in the RCSB Protein Data Bank under accession code 5F09.
650    _2
$a antigeny povrchové $x chemie $x metabolismus $7 D000954
650    _2
$a vazebná místa $7 D001665
650    _2
$a karboxypeptidasy $x chemie $x metabolismus $7 D002268
650    _2
$a katalytická doména $7 D020134
650    _2
$a glutamátkarboxypeptidasa II $x chemie $x metabolismus $7 D043425
650    _2
$a glutamáty $x chemie $x metabolismus $7 D005971
650    _2
$a lidé $7 D006801
650    _2
$a molekulární struktura $7 D015394
650    _2
$a substrátová specifita $7 D013379
650    _2
$a termodynamika $7 D013816
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tykvart, Jan $u Institute of Organic Chemistry and Biochemistry, Gilead Sciences and IOCB Research Centre, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Faculty of Natural Sciences, Charles University in Prague, Czech Republic.
700    1_
$a Schimer, Jiří $u Institute of Organic Chemistry and Biochemistry, Gilead Sciences and IOCB Research Centre, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Faculty of Natural Sciences, Charles University in Prague, Czech Republic.
700    1_
$a Pachl, Petr $u Institute of Organic Chemistry and Biochemistry, Gilead Sciences and IOCB Research Centre, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Navrátil, Václav $u Institute of Organic Chemistry and Biochemistry, Gilead Sciences and IOCB Research Centre, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Faculty of Natural Sciences, Charles University in Prague, Czech Republic.
700    1_
$a Rokob, Tibor András $u Institute of Organic Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
700    1_
$a Hlouchová, Klára $u Institute of Organic Chemistry and Biochemistry, Gilead Sciences and IOCB Research Centre, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Faculty of Natural Sciences, Charles University in Prague, Czech Republic.
700    1_
$a Rulíšek, Lubomír $u Institute of Organic Chemistry and Biochemistry, Gilead Sciences and IOCB Research Centre, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry, Gilead Sciences and IOCB Research Centre, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biochemistry, Faculty of Natural Sciences, Charles University in Prague, Czech Republic.
773    0_
$w MED00008414 $t The FEBS journal $x 1742-4658 $g Roč. 283, č. 13 (2016), s. 2528-45
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27208881 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720124107 $b ABA008
999    __
$a ok $b bmc $g 1239647 $s 984879
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 283 $c 13 $d 2528-45 $e 20160606 $i 1742-4658 $m The FEBS journal $n FEBS J $x MED00008414
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...